AlphaCentric Advisors’s Merck MRK Stock Holding History

AlphaCentric Advisors’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$2.25M	Sell	22,597 -1,403	-6%	-$145K	2.24%	6
2024 Q3	$2.73M	Buy	+24,000	New	+$2.85M	2.03%	4
2022 Q4	–	Sell	-3,000	Closed	-$258K	–	196
2022 Q3	$258K	Buy	+3,000	New	+$268K	0.26%	84
2021 Q4	$613K	Sell	8,000 -1,750	-18%	-$139K	0.18%	57
2021 Q3	$732K	Sell	9,750 -2,250	-19%	-$171K	0.19%	50
2021 Q2	$933K	Sell	12,000 -3,196	-21%	-$238K	0.25%	28
2021 Q1	$1.12M	Buy	15,196 +12,890	+559%	+$951K	0.38%	18
2020 Q4	$180K	Buy	2,306 +1,730	+300%	+$132K	0.08%	74
2020 Q3	$46K	Sell	576 -105	-15%	-$8.22K	0.02%	112
2020 Q2	$50K	Buy	+681	New	+$51.3K	0.03%	87

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AlphaCentric Advisors's MRK Position: Q4 2024 in Review

AlphaCentric Advisors reduced its Merck (MRK) stake by 5.8% in Q4 2024, selling an estimated $145K and leaving 22,597 shares worth $2.25M. The position accounts for 2.24% of the portfolio, ranked #6.

AlphaCentric Advisors first reported a position in MRK in Q2 2020 and has held it in 10 quarters since. The position peaked at $2.73M in Q3 2024. 3,607 funds tracked by Wall St. Rank hold MRK as of Q4 2024.

AlphaCentric Advisors held 22,597 shares of Merck worth $2.25M as of Q4 2024.
AlphaCentric Advisors sold 1,403 Merck shares in Q4 2024, an estimated $145K.
Merck made up 2.24% of AlphaCentric Advisors's portfolio in Q4 2024, its #6 holding.
AlphaCentric Advisors first reported a position in Merck in Q2 2020 and has held it in 10 quarters since.
AlphaCentric Advisors's Merck position peaked at $2.73M in Q3 2024.
3,607 funds tracked by Wall St. Rank held Merck as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.